NCT01199718View on ClinicalTrials.gov

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

September 30, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

CX-4945

CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.

Trial Locations (6)

23502

RECRUITING

Norfolk

29605

RECRUITING

Greenville

45249

RECRUITING

Kettering

97239

RECRUITING

Oregon Health Science University, Portland

97477

RECRUITING

Springfield

98902

RECRUITING

Yakima

Sponsors
All Listed Sponsors
lead

Cylene Pharmaceuticals

INDUSTRY